Pheon Therapeutics

Pheon Therapeutics is a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers.

[Pheon Therapeutics @pheontx]

Read the press release here: https://t.co/hMFslmQmre

[Pheon Therapeutics @pheontx]

@pheontx is pleased to announce 📢 the appointment of accomplished biotech executive, Enoch Kariuki, PharmD, to its Board of Directors as an independent, non-executive director! Read more about Dr. Kariuki's experience in the PR 🗞️, linked in the comments below👇.

[Pheon Therapeutics @pheontx]

📣@pheontx announces the closing of a $120m Series B financing to fund development of its differentiated #ADC pipeline!

[Pheon Therapeutics @pheontx]

Full press release: https://t.co/Ha6r6Kro0C

[Pheon Therapeutics @pheontx]

@Pheontx is excited to announce 📣 the completion of a $120 million #SeriesBfinancing to advance its differentiated #ADC pipeline through proof of concept. Led by TCGX, we welcome Cariad Chester to the board. Stay tuned for more updates coming soon! Link to PR in the thread!

[Pheon Therapeutics @pheontx]

@Pheon_tx is set to be in San Francisco next week, 8-11 January, for the 42nd Annual @jpmorgan Healthcare Conference. Get in touch if you would like to meet with our CEO, Cyrus Mozayeni. #JPM2024 #PheonTherapeutics #Oncology #Innovation #ADCs

[Pheon Therapeutics @pheontx]

@pheontx is pleased to announce the appointment of #oncology expert Arvin Yang, MD, PhD as its new CMO. As a seasoned CMO with over a decade of experience in advancing oncology therapies, he joins us to advance #ADCs for treatment of solid tumors. https://t.co/CxUvOsozgh

[Pheon Therapeutics @pheontx]

Welcome to Jeff Albers on his appointment as Chairman of the @Pheon_tx Board of Directors.
#ADCs #oncology #CompanyGrowth #clinicaldevelopment

[Pheon Therapeutics @pheontx]

@Pheon_tx proudly welcomes Cyrus Mozayeni as its new CEO. With 20+ years of biotech expertise, Cyrus will lead the Company in the next stage of Company growth as we advance our #ADC program targeting hard-to-treat cancers into the clinic. Read more: https://t.co/p1WjTMo2Ku

[Pheon Therapeutics @pheontx]

@Pheon_tx will develop and commercialize an antibody using @Biocytogen's proprietary #RenMice platform to develop a best-in-class ADC as part of an exclusive licensing agreement.

Read more here: https://t.co/zLJzeT4KKQ

[Pheon Therapeutics @pheontx]

We are delighted to announce the successful launch of @pheontx with a $68M #SeriesA to advance novel Antibody-Drug Conjugates for a wide range of hard-to-treat #cancers.

Read more: https://t.co/JHr3a76qIb

#pheontx #ADCs #solidtumors #biotech